{"id":64134,"date":"2026-05-12T15:15:18","date_gmt":"2026-05-12T15:15:18","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/64134\/"},"modified":"2026-05-12T15:15:18","modified_gmt":"2026-05-12T15:15:18","slug":"novartis-india-standalone-net-profit-declines-13-82-in-the-march-2026-quarter-capital-market-news","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/64134\/","title":{"rendered":"Novartis India standalone net profit declines 13.82% in the March 2026 quarter | Capital Market News"},"content":{"rendered":"<p> Last Updated : May 12 2026 | 4:32 PM IST<\/p>\n<p>Sales rise 7.95% to Rs 90.55 crore<\/p>\n<p>Net profit of Novartis India declined 13.82% to Rs 25.25 crore in the quarter ended March 2026 as against Rs 29.30 crore during the previous quarter ended March 2025. Sales rose 7.95% to Rs 90.55 crore in the quarter ended March 2026 as against Rs 83.88 crore during the previous quarter ended March 2025.<\/p>\n<p>For the full year,net profit declined 7.65% to Rs 93.18 crore in the year ended March 2026 as against Rs 100.90 crore during the previous year ended March 2025. Sales declined 0.54% to Rs 354.33 crore in the year ended March 2026 as against Rs 356.27 crore during the previous year ended March 2025.<\/p>\n<p>\u00a0ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.Sales90.5583.88 8 354.33356.27 -1 OPM %22.7728.51 -26.5625.66 &#8211; PBDT30.5634.42 -11 131.61132.61 -1 PBT30.1433.89 -11 129.66130.42 -1 NP25.2529.30 -14 93.18100.90 -8 <\/p>\n<p>Powered by Capital Market &#8211; Live News<\/p>\n<p style=\"font-style: italic;\" id=\"auto_disclaimer\">Disclaimer:  No Business Standard Journalist was involved in creation of this content<\/p>\n<p>First Published: May 12 2026 | 4:32 PM IST<\/p>\n","protected":false},"excerpt":{"rendered":"Last Updated : May 12 2026 | 4:32 PM IST Sales rise 7.95% to Rs 90.55 crore Net&hellip;\n","protected":false},"author":2,"featured_media":14092,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[206,9922,35006],"class_list":{"0":"post-64134","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-novartis","9":"tag-novartis-india","10":"tag-pharmaceuticals-nec"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116562265869155250","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/64134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=64134"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/64134\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/14092"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=64134"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=64134"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=64134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}